Snapshot
Baxter International Inc reported $2.97B of revenue in Q4 2025, up 8.0% year over year, with diluted EPS of $-2.19 and an operating margin of -24.5%.
- Revenue
- $2.97B
- YoY growth
- +8.0%
- Diluted EPS
- $-2.19
- Operating margin
- -24.5%
$2.97B
Revenue
+8.0%
YoY growth
$-2.19
Diluted EPS
-24.5%
Operating margin
01 Key takeaways
What management said
- •Today, we will discuss Baxter's fourth quarter results, along with our financial outlook for the full year 2026.
- •This morning, a press release was issued with our preliminary earnings results and updated outlook.
- •On the call, we will reference operational growth, which excludes the impact of foreign exchange, MSA revenues from Vantive, and the previously announced exit of IV Solutions from China.
- •We will also reference organic growth, which excludes the impact of foreign exchange, MSA revenues from Vantive, and any impact from future business acquisitions or divestitures.
- •Total company adjusted earnings from continuing operations were $0.44 per diluted share.
- •While responses have varied, in general, customers are waiting for additional clarity on the nature and timing of the additional corrections that we will look to deploy.
- •Margins were pressured by both an unfavorable mix of sales as well as some non-recurring items, including inventory adjustments.
- •The Healthcare Systems and Technologies segment had another quarter of consistent performance, including a contribution from the recently launched Connex 360 monitor in the Front Line Care division.
- •As I said during our last earnings call and reiterated last month, I am focused on three main priorities.
- •Most significantly, we are delayering levels of leadership, including removing the segment management layer and embedding critical functional roles directly in each of our businesses.
- •We've also taken actions within our IV Solutions business to rightsize a support footprint to align to the lower demand environment, which we believe is a new baseline in the market.
- •In Pharma, in addition to market demand softness, supply and backorder challenges have impacted revenue and driven unfavorable product mix.
SourcesCompany financials · earnings call
Last updated